ABION INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7,140 KRW | +0.56% |
|
+5.47% | -15.30% |
| Sales 2022 | 2.51B 1.82M 152M | Sales 2023 | 1.27B 926K 77.19M | Capitalization | 164B 119M 9.91B |
|---|---|---|---|---|---|
| Net income 2022 | -19.92B -14.49M -1.21B | Net income 2023 | -29.21B -21.24M -1.77B | EV / Sales 2022 | 45.7 x |
| Net cash position 2022 | 12.4B 9.01M 751M | Net Debt 2023 | 4.38B 3.18M 265M | EV / Sales 2023 | 132 x |
| P/E ratio 2022 |
-6.36
x | P/E ratio 2023 |
-5.53
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 57.84% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.56% | ||
| 1 week | +5.47% | ||
| Current month | +8.68% | ||
| 1 month | +7.69% | ||
| 3 months | -4.42% | ||
| 6 months | +19.20% | ||
| Current year | -15.30% |
1 week
6 550.00
7 910.00
1 month
5 580.007 910.00
Current year
5 580.008 710.00
1 year
4 710.009 720.00
3 years
4 710.0026 450.00
5 years
4 250.0026 450.00
10 years
3 035.0026 450.00
| Managers | Title | Age | Since |
|---|---|---|---|
Young-Gi Shin
CEO | Chief Executive Officer | 53 | 01/10/01 |
Yoon-Soo Kang
DFI | Director of Finance/CFO | 47 | 01/19/01 |
Joon-Young Choi
COO | Chief Operating Officer | 49 | 01/19/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eun-Hyun Jang
BRD | Director/Board Member | 54 | - |
Young-Gi Shin
CEO | Chief Executive Officer | 53 | 01/10/01 |
Joon-Young Choi
COO | Chief Operating Officer | 49 | 01/19/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 7,140 | +0.56% | 311,946 |
| 25/24/25 | 7,100 | -1.53% | 85,615 |
| 24/24/24 | 7,210 | +1.26% | 170,812 |
| 23/24/23 | 7,120 | +5.95% | 197,261 |
| 22/24/22 | 6,720 | -0.74% | 201,744 |
End-of-day quote Korea S.E., April 26, 2024
More quotes
ABION Inc. is a Korea-based company principally engaged in the research, development and sales of pharmaceuticals. Along with its subsidiaries, the Company operates its business through four segments including product segment, contract research organization (CRO) service segment, research segment and other segment. The Product segment produces and sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment provides histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services. The Research segment is engaged in research and development of drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics.
Calendar
10/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -15.30% | 114M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- A203400 Stock
